A5081831577- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Radiomics and Machine Learning in Medical Imaging
- Urologic and reproductive health conditions
- Bladder and Urothelial Cancer Treatments
- MRI in cancer diagnosis
- Urological Disorders and Treatments
- Molecular Biology Techniques and Applications
- Colorectal Cancer Screening and Detection
- Urinary Bladder and Prostate Research
- Renal cell carcinoma treatment
- Urinary and Genital Oncology Studies
- Advanced Radiotherapy Techniques
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Renal and related cancers
- Acute Kidney Injury Research
- AI in cancer detection
- Global Cancer Incidence and Screening
- Surgical Simulation and Training
- Chronic Kidney Disease and Diabetes
- Anatomy and Medical Technology
- Winter Sports Injuries and Performance
- Ureteral procedures and complications
- Radiopharmaceutical Chemistry and Applications
- Cancer, Lipids, and Metabolism
Yale University
2016-2025
Yale New Haven Hospital
2015-2024
VA Connecticut Healthcare System
2016-2024
Smilow Cancer Hospital
2016-2023
Yale Cancer Center
2016-2023
Exelixis (United States)
2023
Bristol-Myers Squibb (Germany)
2023
University of New Haven
2015-2020
Huntsman Cancer Institute
2015
University of Utah
2015
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection provide recommendations prostate cancer screening healthy men who have elected to participate an early detection program. focus on minimizing unnecessary procedures and limiting the of indolent disease. These Insights summarize Panel's most significant discussions 2016 guideline update, which included issues surrounding high-risk populations (ie, African Americans, BRCA1/2 mutation...
The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations individuals with a prostate who opt to participate in an early detection program after receiving the appropriate counseling on pros and cons. These Insights summary of recent updates regard testing protocol, use multiparametric MRI, management negative biopsy results optimize clinically significant cancer minimize indolent disease.
In April 2017, the US Preventive Services Task Force (USPSTF) published a draft guideline that reversed its 2012 guidance advising against prostate-specific antigen (PSA)-based screening for prostate cancer in all men (grade D), instead endorsing individual decision-making aged 55 to 69 years C).To evaluate changes rates of PSA testing after revisions USPSTF on screening.This retrospective cohort study used deidentified claims data from Blue Cross Shield beneficiaries 40 89 January 1, 2013,...
The objective of this study is to determine the frequency clinically significant cancer (CSC) in Prostate Imaging Reporting and Data System (PI-RADS) category 3 (equivocal) lesions prospectively identified on multiparametric prostate MRI identify risk factors (RFs) for CSC that may aid decision making.Between January 2015 July 2016, a total 977 consecutively seen men underwent MRI, 342 MRI-ultrasound (US) fusion targeted biopsy. A 474 were retrospectively reviewed, 111 scored as PI-RADS...
The ability of medical image analysis deep learning algorithms to generalize across multiple sites is critical for clinical adoption these methods. Medical imging data, especially MRI, can have highly variable intensity characteristics different individuals, scanners, and sites. However, it not practical train with data from all imaging equipment sources at possible Intensity normalization methods offer a potential solution working multi-site data. We evaluate five on training neural network...
Background Most Prostate Imaging–Reporting and Data System (PI‐RADS) 3 lesions do not contain clinically significant prostate cancer (CSPCa; grade group ≥2). This study was aimed at identifying clinical magnetic resonance imaging (MRI)–derived risk fac‐ tors that predict CSPCa in men with PI‐RADS lesions. Methods analyzed the detection of who underwent MRI‐targeted biopsy for Multivariable logistic regression models goodness‐of‐fit testing were used to identify variables associated CSPCa....
Although the Decipher genomic classifier has been validated as a prognostic tool for several prostate cancer endpoints, little is known about its role in assessing risk of biopsy reclassification patients on active surveillance, key event that often triggers treatment.To evaluate association between scores and Gleason upgrading among surveillance.This was retrospective cohort study with low- favorable intermediate-risk surveillance who underwent biopsy-based testing part their clinical...
Although surgery is less commonly selected as treatment for localized prostate cancer (PCa) patients age, outcomes among older treated with radical prostatectomy remain unclear. The objective of this study was to compare survival across non-definitive therapy (NDT), radiotherapy, and (RP) men than 80 years old. Using the SEER-17 database, we identified ≥80 at diagnosis in 2000-2021 who were initially managed NDT, or RP. We compared overall (OS) cancer-specific (PCSS). 53,437 PCa≥80 including...
Purpose: Prostate-specific membrane antigen positron emission tomography (PSMA-PET) improves prostate cancer (PCa) localization, particularly in biochemical recurrence (BCR). The primary objective was to assess management patterns after PSMA-PET for BCR at 2 academic centers. Methods: This study evaluated clinical within 6 months first patients with local therapy. Management categories included no treatment, therapy, systemic and metastasis-directed therapy (MDT). We also decision variation...
Purpose of review This presents the latest research in tissue-based genomic testing localized prostate cancer (PCa). Here we explore current and most commonly used assays, their clinical applications, challenges, future testing. Recent findings The management PCa has evolved with integration offering a more personalized approach to risk stratification treatment decision-making. Traditional markers such as PSA levels Gleason scores are often insufficient capturing clinically significant due...
The purpose of this study was to determine imaging and clinical features associated with Prostate Imaging Reporting Data System (PI-RADS) category 5 lesions identified prospectively at multiparametric MRI (mpMRI) that were found benign MRI-ultrasound fusion targeted biopsy.Between January 2015 July 2016, 325 men underwent prostate mpMRI followed by biopsy 420 assessed PI-RADS version 2. frequency clinically significant cancer (defined as Gleason score ≥ 7) among determined. Lesions...